{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:56:20Z","timestamp":1770144980603,"version":"3.49.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012655","name":"Qilu Hospital of Shandong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Both regorafenib and trifluridine\/tipiracil (TAS-102) monotherapies have shown significant but limited survival benefits in metastatic colorectal cancer (mCRC) cases who progress after standard treatments. This study aimed to evaluate the efficacy and safety of regorafenib plus biweekly TAS-102 in refractory mCRC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this single-arm multicenter phase II trial (ChiCTR2300071752), eligible patients received regorafenib at 120\u00a0mg\/day for 21 days in a 4-week cycle or were treated with a dose-escalation strategy (80\u00a0mg\/day, followed by weekly increase of 40\u00a0mg to 120\u00a0mg\/day). TAS-102 was administered biweekly (30\u00a0mg\/m2 bid on days 1-5). The primary endpoint was progression-free survival (PFS). The secondary endpoints included safety, response rate (ORR), disease control rate (DCR), and overall survival (OS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Between March 1, 2022 and December 1, 2023, 28 patients were enrolled. Totally 24 patients had at least one response evaluation. Median PFS and OS were 4.9 months (95% CI, 4.2-5.6) and 15.4 months (95% CI, 11.1-19.7). The ORR was 8.3% and the DCR was 83.3%. Grade 3 or 4 treatment-related adverse events occurred in 21.4% of patients, including hypertension (7.1%), neutropenia (7.1%), thrombocytopenia (3.6%), and hoarseness (3.6%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Regorafenib plus biweekly TAS-102 showed promising benefits in refractory mCRC cases, and adverse events were generally tolerable and manageable.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>(ClinicalTrials.gov Identifier: ChiCTR2300071752. IRB Approved: KYLL-202203-026-1.)<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf129","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T19:08:23Z","timestamp":1750964903000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of regorafenib plus biweekly trifluridine\/tipiracil for refractory metastatic colorectal cancer: a multicenter single-arm phase II trial"],"prefix":"10.1093","volume":"30","author":[{"given":"Xiangling","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital of Shandong University , Jinan 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Linyi Cancer Hospital , Linyi ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Sha","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Comprehensive Treatment of Cancer, Shandong Provincial Hospital Affiliated to Shandong First Medical University , Jinan 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haipeng","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Weifang People\u2019s Hospital , Weifang ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuihua","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital of Shandong University , Jinan 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuguang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital of Shandong University , Jinan 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Weifang Yidu People\u2019s Hospital , Weifang ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunxia","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital of Shandong University , Jinan 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changlun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Jining Medical University , Jining ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanglian","family":"Shan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Xintai People\u2019s Hospital , Taian ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital of Shandong University , Jinan 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9866-3029","authenticated-orcid":false,"given":"Xiaorong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital of Shandong University , Jinan 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9110-5370","authenticated-orcid":false,"given":"Jing","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital of Shandong University , Jinan 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"2025062615081772100_CIT0001","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"2025062615081772100_CIT0002","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/cells13030245","article-title":"Update on targeted therapy and immunotherapy for metastatic colorectal cancer","volume":"13","author":"Underwood","year":"2024","journal-title":"Cells"},{"key":"2025062615081772100_CIT0003","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet (London, England)"},{"key":"2025062615081772100_CIT0004","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol."},{"key":"2025062615081772100_CIT0005","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med."},{"key":"2025062615081772100_CIT0006","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","article-title":"Results of a randomized, double-blind, placebo-controlled, phase III Trial of Trifluridine\/Tipiracil (TAS-102) monotherapy in asian patients with previously treated metastatic colorectal cancer: the TERRA study","volume":"36","author":"Xu","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025062615081772100_CIT0007","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial","volume":"319","author":"Li","year":"2018","journal-title":"JAMA."},{"key":"2025062615081772100_CIT0008","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet (London, England)"},{"key":"2025062615081772100_CIT0009","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.clcc.2017.10.016","article-title":"A comparison of regorafenib and TAS-102 for metastatic colorectal cancer: a systematic review and network meta-analysis","volume":"17","author":"Abrahao","year":"2018","journal-title":"Clin Colorectal Cancer."},{"key":"2025062615081772100_CIT0010","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1634\/theoncologist.2017-0275","article-title":"Propensity score analysis of regorafenib versus trifluridine\/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): a Japanese society for cancer of the colon and rectum multicenter observational study","volume":"23","author":"Moriwaki","year":"2018","journal-title":"Oncologist."},{"key":"2025062615081772100_CIT0011","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1038\/s41598-023-29706-6","article-title":"Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine\/tipiracil plus bevacizumab","volume":"13","author":"Matsumoto","year":"2023","journal-title":"Sci Rep."},{"issue":"suppl_1","key":"2025062615081772100_CIT0012","first-page":"S1","article-title":"PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine\/tipiracil (t\/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC)","volume":"35","author":"DUCREUX","year":"2024","journal-title":"ESMO Gastrointestinal Congress"},{"key":"2025062615081772100_CIT0013","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med."},{"key":"2025062615081772100_CIT0014","doi-asserted-by":"publisher","first-page":"S439","DOI":"10.1016\/j.annonc.2023.09.1804","article-title":"613P Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial","volume":"34","author":"Prager","year":"2023","journal-title":"Ann Oncol."},{"key":"2025062615081772100_CIT0015","first-page":"119","article-title":"The mechanism of action of regorafenib in colorectal cancer: a guide for the community physician","volume":"17 Suppl 12","author":"Grothey","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"2025062615081772100_CIT0016","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.2217\/fon-2021-0278","article-title":"A phase I dose-escalation study of third-line regorafenib with trifluridine\/tipiracil in metastatic colorectal cancer","volume":"17","author":"Moehler","year":"2021","journal-title":"Future Oncol (London, England)"},{"key":"2025062615081772100_CIT0017","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s10147-022-02243-4","article-title":"Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study)","volume":"27","author":"Matsuoka","year":"2022","journal-title":"Int J Clin Oncol."},{"key":"2025062615081772100_CIT0018","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/bjc.2012.274","article-title":"Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours","volume":"107","author":"Doi","year":"2012","journal-title":"Br J Cancer."},{"key":"2025062615081772100_CIT0019","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","article-title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study","volume":"20","author":"Bekaii-Saab","year":"2019","journal-title":"Lancet Oncol."},{"key":"2025062615081772100_CIT0020","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2022.09.037","article-title":"A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)","volume":"177","author":"Argil\u00e9s","year":"2022","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"2025062615081772100_CIT0021","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1186\/s12885-023-11720-6","article-title":"Appropriate dose of regorafenib based on body weight of colorectal cancer patients: a retrospective cohort study","volume":"23","author":"Nakashima","year":"2023","journal-title":"BMC Cancer"},{"key":"2025062615081772100_CIT0022","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.ejca.2015.02.013","article-title":"Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial","volume":"51","author":"Argil\u00e9s","year":"2015","journal-title":"Eur J Csancer (Oxford, England : 1990)"},{"key":"2025062615081772100_CIT0023","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1002\/cncr.31552","article-title":"Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer","volume":"124","author":"Sanoff","year":"2018","journal-title":"Cancer."},{"key":"2025062615081772100_CIT0024","doi-asserted-by":"publisher","first-page":"e0190497","DOI":"10.1371\/journal.pone.0190497","article-title":"Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: a single center, retrospective study","volume":"13","author":"Lin","year":"2018","journal-title":"PLoS One."},{"key":"2025062615081772100_CIT0025","doi-asserted-by":"publisher","first-page":"e1855","DOI":"10.1634\/theoncologist.2020-0643","article-title":"Phase Ib\/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)","volume":"25","author":"Satake","year":"2020","journal-title":"Oncologist."},{"key":"2025062615081772100_CIT0026","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1093\/oncolo\/oyae013","article-title":"The efficacy of immune checkpoint inhibitors in microsatellite stable colorectal cancer: a systematic review","volume":"29","author":"Guven","year":"2024","journal-title":"Oncologist."},{"key":"2025062615081772100_CIT0027","doi-asserted-by":"publisher","first-page":"101614","DOI":"10.1016\/j.esmoop.2023.101614","article-title":"Real-world evidence of trifluridine\/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan","volume":"8","author":"Kagawa","year":"2023","journal-title":"ESMO open"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf129\/63504884\/oyaf129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf129\/63504884\/oyaf129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T19:08:24Z","timestamp":1750964904000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf129\/8164543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf129","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,6]]},"article-number":"oyaf129"}}